他汀类药物和体外膜肺氧合装置植入后血液相容性不良事件的关系

Abstract
Figure/Table
References (26)
Related Citation (2)

Download: PDF (600 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the relationship of hemocompatibility related clinical adverse events (HRAEs) and statin treatment after extra-corporeal membrane oxygenation (ECMO) implantation in patients with postoperative cardiac shock (PCS). Methods Clinical data of 280 patients who received ECMO implantation in Fuwai Hospital, Peking Union Medical College from February 2008 to April 2016 were collected to observe the occurrence of HRAEs after taking statins, and the basic characteristics, complications and other medication of patients were recorded. COX proportional hazard ratio regression and other methods were used to study the effect of statins on HRAEs, and propensity score was used for matching and re-analysis. Results HRAEs occurred in 40 (18.87%) and 17 (25.00%) patients in the non-statin group and 68 patients in the statin group, respectively. Log-rank test showed that patients taking statins were more likely to develop HRAEs (P = 0.014), and the incidence of bleeding events was higher in the statin group than in the non-statin group (P ＜ 0.05). Multivariate analysis showed that statins may be a risk factor for HRAEs [HR (95%CI) =2.149(1.100-4.201), P = 0.025]. After matching using a propensity score, HRAEs were more common in patients taking statins than in those not taking statins (P = 0.008). Conclusion PCS patients are prone to HRAEs with statins after ECMO implantation in 60 days. The results need to be verified by large sample studies.

Key words： Extra-Corporeal Membrane Oxygenation Hemocompatibility related clinical adverse events Hemocompatibility score Statins

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LEI Bai HOU Jianfeng HU Shengshou

Cite this article:

LEI Bai HOU Jianfeng HU Shengshou. Relationship between statins and hemocompatibility related clinical adverse events after extra-corporeal membrane oxygenation implantation#br#[J]. 中国医药导报, 2021, 18(32): 66-70.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I32/66

[1] Mehra MR. The burden of haemocompatibility with left ventricular assist systems：a complex weave [J]. Eur Heart J，2019，40（8）：673-677.
[2] Chung M，Cabezas FR，Cabezas JI，et al. Hemocompatibility-Related Adverse Events and Survival on Venoarterial Extracorporeal Life Support：An ELSO Registry Analysis [J]. JACC Heart Fail，2020，8（11）：892-902.
[3] Mehra MR，Naka Y，Uriel N，et al. A fully magnetically levitated circulatory pump for advanced heart failure [J]. N Engl J Med，2017，376（5）：440-450.
[4] Imamura T，Nguyen A，Kim G，et al. Optimal haemodynamics during left ventricular assist device support are associated with reduced haemocompatibility-related adverse events [J]. Eur J Heart Fail，2019，21（5）：655-662.
[5] Willey JZ，Gavalas MV，Trinh PN，et al. Colombo PC. Outcomes after stroke complicating left ventricular assist device [J]. J Heart Lung Transplant，2016，35（8）：1003-1009.
[6] Roever L，Resende ES，Mehra MR. Vulnerable Brain and Ventricular Assist Devices [J]. Stroke，2016，47：2677-2678.
[7] Rogers JG，Pagani FD，Tatooles AJ，et al. Intrapericardial left ventricular assist device for advanced heart failure[J]. N Engl J Med，2017，376（5）：451-460.
[8] Mandeep MR，Sundareswaran KS，Uriel N. Response by Mehra to Letter Regarding Article，“ Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months：A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure” [J].Circulation，2017，136（19）：1872-1873.
[9] Mehta P，Imamura T，Belkin M，et al. Neurohormonal blockade reduces adverse events during LVAD support [J]. J Heart Lung Transplant，2018，37（4）：180-181.
[10] 侯剑峰，陈凯.体外膜肺氧合与主动脉球囊反搏联合辅助救治心血管外科术后心原性休克：阜外医院单中心十一年经验总结[J].中国循环杂志，2019，34（1）：66-71.
[11] Maltais S，Kilic A，Nathan S，et al. Prevention of Heart Mate Ⅱ pump thrombosis through clinical management：the PREVENT multi-center study [J]. J Heart LungTransplant，2017，36（1）：1-12.
[12] Sparrow CT，Nassif ME，Raymer DS，et al. Preoperative right ventricular dysfunction Is associated with gastrointestinal bleeding in patients supported with continuous-flow left ventricular assist devices [J]. JACC Heart Fail，2015，3（12）：956-964.
[13] 中国医师协会体外生命支持专业委员会．成人体外膜氧合循环辅助专家共识[J]．中华医学杂志，2018，98（12）：886-894．
[14] Li B，Sun G，Cheng Z，et al. Analysis of nosocomial infections in post-cardiac surgery extracorporeal membrane oxygenation support therapy [J]. Heart Surg Forum，2018， 21（5）：E387-E391.
[15] 侯剑峰，陈凯.体外膜肺氧合救治心血管术后心原性休克患者的研究[J].中国循环杂志，2019，34（5）：492-497.
[16] 陈虹.高脂血症与血液流变学部分指标的关系[J].中国疗养医学，2012，21（12）：1151-1152．
[17] Wang C，Zhang L，Qin T，et al. Extracorporeal membrane oxygenation in trauma patients：a systematic review[J]. World J Emerg Surg，2020，15（1）：1-14.
[18] Menaker J，Galvagno S，Rabinowitz R，et al. Epidemiology of blood stream infection in adult extracorporeal membrane oxygenation patients：a cohort study [J]. Heart Lung，2019，48（3）：236-239.
[19] Imamura T，Nguyen A，Rodgers D，et al. Omega-3 therapy is associated with reduced gastrointestinal bleeding in patients with continuous-flow left ventricular assist device [J]. Circ Heart Fail，2018，11（10）：e005082.
[20] Nakamura M，Imamura T，Hori M，et al. Regulation of angiopoietin-2 before and after mechanical circulatory support therapy [J]. Asaio J，2021，67（1）：53-58.
[21] Thomas J，Kostousov V，Teruya J. Bleeding and thrombotic complications in the use of extracorporeal membrane oxygenation [J]. Semin Thromb Hemost，2018，44（1）：20-29.
[22] Sandner SE，Zimpfer D，Zrunek P，et al. Age and outcome after continuous flow left ventricular assist device as a bridge to transplantation[J]. J Heart Lung Transplant，2009，28：367-372.
[23] Sandner SE，Nolz R，Loewe C，et al. Routine preoperative aortic computed tomography angiography is associated with reduced risk of stroke in coronary artery bypass grafting：a propensity-matched analysis [J]. Eur J Cardiothorac Surg，2020，57（4）：684-690.
[24] Lang NW，Schwihla I，Weihs V，et al. Survival rate and outcome of extracorporeal life support （ECLS） for treatment of acute cardiorespiratory failure in trauma patients [J]. Sci Reports 2019，9（1）：1-6.
[25] Lushaj EB，Badami A，Osaki E，et al. Impact of age on outcomes following continuous flow left ventricular assist device implantation [J]. Interact Cardiovasc Thorac Surg，2015，20：743-748.
[26] Lushaj EB，Bartlett HL，Lamers LJ，et al. Technical Performance Score Predicts Perioperative Outcomes in Complex Congenital Heart Surgery Performed in a Small-to-Medium-Volume Program [J]. Pediatr Cardiol，2020，41（1）：88-93.